SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL

PartnershipCannEpil®Positive

AI Analysis

Summary

Splash Beverage Group acquired exclusive global rights to CannEpil®, an epilepsy therapy with established European patient access, through a licensing agreement with Argent BioPharma Limited. The drug has FDA engagement and U.S. development potential.

Outcome Details

Exclusive global licensing agreement for CannEpil®

Importance:6/10

Sentiment:

0.60

licensingexclusiveglobal rightsepilepsyFDA engagementEuropean patient access

Related Companies

$SBEV $RGT

Read the original article

Published by PR Newswire Pharma on July 7, 2026 10:13 AM

Read Original